VRTX - Vertex Pharmaceuticals Inc
A biotechnology company that transformed cystic fibrosis treatment with its Trikafta franchise, and is now expanding into pain management and other genetic diseases.
Finlify Score
39.5 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$450.46
+1.24%
52W Range
$362.50 - $507.92
Market Cap
$110.2B
+1.2%Compared to previous day
2026 Q1 Revenue
$3.0B
-6.4%Changes from last reporting quarter
2026 Q1 EPS
$4.02
Diluted shares
Analyst Rating
40 analysts in latest ratings feed
RSI
58.2
40-70 moderate
2Y Range Position
56%
-13.4% from high / +24.3% from low
Beta
0.31
Relative to market benchmark
MACD
1.16
MACD line 2.17 / signal line 1.01
Fundamental Trend
Growth 31.2Financial Health
Quality 73.4Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID39.5 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $3.0B-6.4% | $3.2B+3.7% | $3.1B+3.8% | $3.0B+7.0% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.1B-5.6% | $1.2B+1.7% | $1.2B+3.0% | $1.2B+82.7% |
| Net Income | $1.0B-13.4% | $1.2B+10.0% | $1.1B+4.8% | $1.0B+59.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for VRTX is AVOID, with an overall Finlify Score of 38.9 out of 100, which suggests a generally unfavorable quantitative outlook for the asset.
Technical
The low Relative Strength score of 24.2/100 and Accumulation/Volume score of 35.1/100 may indicate a lack of strong buying interest or underperformance compared to peers. Recent short-term returns show a slight decline, with the asset down -1.2% over 20 days and -1.5% over 60 days, while trading -10.9% below its 52-week high.
Fundamentals
Despite a relatively strong Financial Quality score of 73.4/100, the Fundamental Trend score of 31.2/100 appears to be a notable detractor. Valuation metrics such as a P/E of 28.6x, P/B of 6.2x, and P/S of 9.4x may indicate a premium valuation. The asset appears to have low volatility with a Beta of 0.3 and does not offer a dividend yield.
Macro Context
The current macro environment, characterized by an inverted yield curve (10Y-2Y spread of 0.4%) and elevated inflation metrics (CPI YoY at 4.3%), could suggest a cautious economic outlook. For a biotechnology company like VRTX with a low beta of 0.3, this environment might imply a relatively stable but potentially constrained growth landscape.
Key Risks
- Low Finlify component scores for Relative Strength (24.2/100), Accumulation/Volume (35.1/100), and Fundamental Trend (31.2/100) may indicate underlying weaknesses.
- The asset's valuation, with a P/E of 28.6x and P/S of 9.4x, appears elevated, which could limit future upside potential.
- Recent negative short-term returns (-1.2% over 20 days, -1.5% over 60 days) and trading -10.9% below its 52-week high could suggest a lack of positive momentum.